We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

Fund managers haven’t disclosed any holdings of SMMT yet.

SMMT Hedge Fund Activity: Q1 2026 in Review

222 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q1 2026, worth a combined $2.25B — up 9.3% from $2.06B a quarter earlier.

Buyers outnumbered sellers: 58 funds opened new SMMT positions and 37 closed out — a net gain of 21 holders — while 83 added to existing stakes and 49 trimmed.

The largest buyer was UBS Group, adding an estimated $45.4M. The largest seller was Fidelity Investments, cutting an estimated $40.6M.

  • 222 institutional investors held Summit Therapeutics (SMMT) as of Q1 2026, up from 206 in Q4 2025.
  • Funds reported $2.25B of Summit Therapeutics stock for Q1 2026, up 9.3% quarter-over-quarter.
  • 58 funds opened new Summit Therapeutics positions in Q1 2026 and 37 closed out, a net change of +21 holders.
  • The largest Summit Therapeutics buyer in Q1 2026 was UBS Group, an estimated $45.4M added.
  • The largest Summit Therapeutics seller in Q1 2026 was Fidelity Investments, an estimated $40.6M sold.

Based on aggregated 13F filings for Q1 2026.